- The new Gateway Labs site will occupy 44,000 square feet at 2300 Market in Philadelphia.
- Biotechs will have access to fully equipped wet lab facilities and strategic scientific engagement.
- Lilly's U.S. Gateway Labs now include Boston, South San Francisco, San Diego, and Philadelphia.
- Since 2019, Gateway Labs companies have raised over $3 billion for more than 50 therapeutic programs.
New Gateway Labs Site
Eli Lilly and Company announced plans to open a new Lilly Gateway Labs site in Philadelphia. The facility will be located at 2300 Market, a life sciences hub developed by Breakthrough Properties, and will cover 44,000 square feet.
Support for Biotech Innovation
The site will host early-stage biotech companies, providing them with fully equipped wet lab facilities and strategic scientific engagement. This initiative aims to support the development of next-generation medicines by offering both infrastructure and expert guidance.
Expansion Strategy
Philadelphia joins Boston, South San Francisco, and San Diego as part of Lilly's U.S. Gateway Labs network. These locations are chosen for their strong research communities and entrepreneurial spirit, serving as catalysts for life sciences innovation.
Impact Since 2019
Since the first Gateway Labs site opened in 2019, resident companies have collectively raised over $3 billion, advancing more than 50 therapeutic programs. This underscores the effectiveness of the Gateway Labs model in fostering biotech growth and innovation.
